Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial

By afschroeder • September 1, 2026

Baden LR, Shah NS, Liu STH, Cohen J, Moy J, Kumar A, McComsey GA, Chen P, Floris-Moore M, Singer NG, Fernandez I, Slandzicki AJ, Wiley Z, Kadl A, Kaminsky DA, Hsu H, Walker TA, Hope AA, Ostrosky-Zeichner L, Goldman JD, Peluso MJ, Patterson TF, Parthasarathy S, Mullington JM, Bolin P Jr, Jolley SE, Krishnan JA, Castro M, Hodder SL, Pemu P, Chu HY, Risbano MG, Jerath MR, Mylonakis E, Hurt RT, Alicic R, Azad NS, Sala MA, Harkins MS, Parsonnet J, Stafford N, Robinson P, Hussain S, Qiao X, Hawk ST, Lillestol M, Erdmann N, Gebo KA, Sudhindra P, Sassine J, Marshall GD, Chatterjee T, Morse CG, Kedar E, Stringer WW, Frontera JA, Jordan M, Blaskewicz C, Santana JL, Foot RA, Wongtrakool C, McCarthy MW, Mehari A, Amon A, Cohen AK, Jain N, Maughan C, Lindsay D, Olson R, Broderick S, Rowe P, O'Brien SM, Walt DR, Levy BD, Jason LA, Low PA, Shibao CA, Make B, Bateman L, Redline S, Knopman D, Hernandez AF, Nolen TL, Reist C, Berdan L, Whitley R, Zimmerman KO; RECOVER-VITAL Clinical Trial Group. Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2026 Aug 31:S1473-3099(26)00406-8. doi: 10.1016/S1473-3099(26)00406-8. Epub ahead of print. PMID: 42673984.

Tags: Cedars Sinai DoM, Publications, Pulmonary, Critical Care & Sleep Medicine

Bioactive Lipids of Cardiorespiratory Fitness Insights From Exercise Models in Humans, Mice, and Burmese Pythons

Guseh JS, Roshandelpoor A, Alotaibi M, Zarbafian S, Lau ES, Kuznetsov A, Rosenzweig A, Saeidi N, Choudhary A, Jain M, Cheng S, Lewis GD, Ho[...]

Improved plaque composition from intensive medical treatment in women with angina and non-obstructive coronary disease

Lenell J, Flores Tomasino G, Han D, Wolny R, Park C, Grodecki K, Kwiecinski J, Xing E, Manral N, Asebiomo F, Goyal D, Calsavara VF,[...]

Mechanical Thrombectomy Versus Anticoagulation Alone in Intermediate-High Risk PE: Improved Functional 90-Day Outcomes in STORM-PE RCT

Rosovsky RP, Konstantinides SV, Weinberg I, Dohad SY, Rosol Z, Stępniewski J, Moriarty JM, Parikh SA, Holden A, Channick RN, McDonald B, Nagarsheth KH, Matusov[...]